# Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis

> **NCT02014623** · PHASE4 · COMPLETED · sponsor: **Bayside Health** · enrollment: 51 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **OTHER:** Grass pollen sublingual immunotherapy tablet
- **DRUG:** Control

## Key facts

- **NCT ID:** NCT02014623
- **Lead sponsor:** Bayside Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2019-11-15
- **Final completion:** —
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02014623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02014623, "Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02014623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*